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cost of managing a dry eye patient was $783 in the US from the payers’ perspective, 
with $678, $771, and $1267 for mild, moderate, and severe patients separately. The 
overall direct costs of DED for the health care system was $3.84 billion based on the 
prevalence of DED. The average annual direct cost for self-treated patients using OTC 
treatment or nutritional supplements was estimated as $126 per patient. The annual 
productivity loss per full-time worker with DED ranges from $12, 569 to $18,168 
depending on the severity of symptoms. The sensitivity analysis suggested that the 
estimated mean direct cost per DED patient seeking professional medical care ranges 
from $757 to $809 approximately. Multiple one-way sensitivity analysis suggested 
the cost estimate was most sensitive to the variation in the distribution of severity of 
symptoms, the frequency of ophthalmologist visits, prevalence of the combined use of 
punctal plugs and cyclosporine, the frequency of optometrist, and compliance with 
cyclosporine by severe patients. CONCLUSIONS: DED poses a substantial amount 
of economic burden for the payer and the society with the indirect costs substantially 
outweighing the direct costs.
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COST EFFECTIVENESS ANALYSIS OF THE ACRYSOF CACHET PHAKIC 
INTRAOCULAR LENS
Fisher M1, Waycaster C2, Vanoli A1, Muston D1
1Heron Evidence Development Limited, Luton, UK, 2Alcon Laboratories Inc., Fort Worth, 
TX, USA
OBJECTIVES: To determine the cost-effective threshold price of the AcrySof Cachet 
phakic intraocular lens (PIOL) relative to the currently marketed Visian and Artisan 
PIOLs in the US. METHODS: We developed a Markov cost-effectiveness model that 
compared the Cachet to the Visian and Artisan PIOLs in a hypothetical cohort of 
patients with moderate to high myopia. A payer perspective was adopted. Costs and 
effectiveness results were discounted at 3% over a 40 year time horizon. Effectiveness 
was expressed as vision adjusted life years (VALYs). VALYs represent a quantiﬁcation 
of the beneﬁts derived from various levels of visual acuity (VA) accumulated over time. 
VA outcome probabilities were taken directly from the CE Mark (Cachet) and FDA 
approved PIOL product labels. The prices of the Visian and Artisan PIOLs were $750 
and $695 respectively. Patients with less than 20/20 VA were assumed to require either 
glasses and/or contact lenses. PIOL, contact lenses and eye glasses costs were based 
on 2009 data from MarketScope and the Vision Watch Report. Probabilities for 
adverse events and associated procedures were derived from PIOL product labels and 
physician interviews. Surgical and drug costs were estimated using reference based 
physician fee estimates and the Medi-Span Price Rx database. Uncertainty was 
addressed through univariate and probabilistic sensitivity analysis (PSA). RESULTS: 
The base-case cost-effectiveness model indicated that the Cachet PIOL economically 
dominated the Visian PIOL up to a threshold price of $1587, and the Artisan PIOL 
up to a threshold price of $2373. The PSA showed that at these prices, the probabilities 
that the Cachet dominated were 59% and 63% respectively. CONCLUSIONS: Given 
its greater efﬁcacy and favourable adverse events proﬁle, the Cachet PIOL was eco-
nomically dominant up to a price twice that of the Visian PIOL and three times that 
of the Artisan PIOL with a considerable degree of certainty.
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COST-EFFECTIVENESS STUDY ON THE USE OF TERBINAFINE VS. 
ITRACONAZOLE IN THE TREATMENT OF ONYCHOMYCOSIS IN 
MEXICO: AN INSTITUTIONAL PERSPECTIVE BASED ON THE RESULTS 
OF THE L.I.O.N. STUDY
Briones B, Garcia F
Novartis Farmaceutica, Mexico City, DF, Mexico
OBJECTIVES: To examine whether terbinaﬁne or itraconazole is a more cost-effective 
treatment for onychomycosis in an institutional setting in Mexico. METHODS: A 
cost-effectiveness analysis was designed; a decision tree with bayesian approach was 
used to model the cost-effectiveness of terbinaﬁne vs. itraconazole in the treatment of 
onychomycosis in Mexico. The perspective was from the Mexican Institute of Social 
Security (IMSS). Discount rate was not used because the time horizon was less than 
1 year. Resource use data was taken from IMSS. Cost data for medications was 
obtained from a local drug distributor database (NADROSA Aug 2009), assuming 
terbinaﬁne dosing scheme as 250 mg daily for 3 months, and itraconazole dosing 
scheme as 400 mg daily for 7 days every 4 weeks for 3 months (pulse dosing scheme). 
Cost data for physician consult was estimated as a ﬁxed-variable. As this analysis was 
performed from an institutional perspective, no other costs were identiﬁed to be 
required for the treatment of onychomycosis. Using data from the L.I.O.N. clinical 
study, mycological cure success rates were estimated for both treatments as ﬁrst 
options; for mycological cure failures, re-treatment costs were estimated using a second 
terbinaﬁne scheme in both groups and an additional physician consult. Total costs per 
patient were determined and incremental cost-effectiveness ratios were calculated. A 
Monte Carlo (100,000 iterations) simulation was performed to reduce the error <0.03. 
A probabilistic sensitivity analysis was performed. RESULTS: The incremental cost 
analysis revealed a total cost of $3823 for terbinaﬁne vs. $7152 for itraconazole (both 
in Mexican pesos, p < 0.001) per patient successfully treated. Terbinaﬁne provides 
superior total health beneﬁts than itraconazole regardless of willingness to pay. The 
sensitivity analysis conﬁrmed the robustness of the model. CONCLUSIONS: From an 
institutional perspective, terbinaﬁne is a more cost-effective (dominant) choice than 
itraconazole for treating onychomycosis in Mexico.
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THE COST-EFFECTIVENESS OF ISOTRETINOIN IN PATIENTS WITH 
MODERATE-TO-SEVERE ACNE VULGARIS
Shin J, Hay J
University of Southern California, Los Angeles, CA, USA
OBJECTIVES: To assess from a societal perspective whether isotretinoin (13-cis-ret-
inoic acid) or oral antibiotics in combination with topical preparations is the more 
cost-effective ﬁrst-line treatment of moderate-to-severe acne vulgaris. METHODS: A 
decision-tree model was used to simulate therapy costs and effectiveness. All estimates 
of cost and effectiveness were obtained from the literature or expert opinion. The 
cost-effectiveness ratio was reported as incremental cost per quality-adjusted life-year 
(QALY) gained. The time horizon was 2 years. Costs and QALYs were discounted by 
a monthly rate of 0.0025%, which is equivalent to an annual rate of 3%. All costs 
were adjusted to 2009 US dollars. A one-way sensitivity analysis was used to determine 
the robustness of the model’s results. The model was developed using Microsoft Excel. 
RESULTS: Isotretinoin increases discounted costs by $1,486 and discounted QALYs 
by 0.071 years when compared to conventional therapy of oral antibiotics and topical 
preparations. This resulted in an incremental cost-effectiveness ratio (ICER) of 
$20,930 per QALY gained for the base case. The results of the model were insensitive 
to most model parameters except for the probabilities associated with achieving 
adequate response or relapse while on therapy. The biggest change in the ICER (204% 
increase) was caused by a 17% increase in the probability of maintaining adequate 
response (no relapse) with conventional therapy. Although the ICER was sensitive to 
these probability values, the highest ICER value of $63,602/QALY found from the 
sensitivity analysis was still below the threshold for cost-effectiveness. CONCLU-
SIONS: Isotretinoin was more costly and also more effective than conventional 
therapy. These results did not change when model parameters were varied in the 
sensitivity analysis. Assuming a $120,000/QALY threshold for cost-effectiveness, 
isotretinoin was cost-effective in the ﬁrst-line treatment of moderate-to-severe inﬂam-
matory acne.
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COMPARING FIXED-COMBINATION THERAPIES FOR TREATING 
PATIENTS WITH OPEN-ANGLE GLAUCOMA IN A MANAGED CARE 
ENVIRONMENT
Makhija DU1, Seo J1, Sansgiry SS2
1University of Houston, Houston, TX, USA, 2University Of Houston, Houston, TX, USA
OBJECTIVES: Glaucoma, a chronic disorder that requires lifelong treatment, creates 
a ﬁnancial burden on patient and health care payers. This study compared ﬁxed-
combination therapies in patients with open-angle glaucoma, namely, Latanoprost 
with Timolol (LT), Dorzolamide with Timolol (DT), and Brimonidine with Timolol 
(BT). METHODS: A cost effectiveness analysis was conducted by extracting data from 
published literature and primary data collected from pharmacy stores. The study was 
conducted from a managed care perspective with drug utilization for a period of 12 
months. A decision analytic model was developed and incremental cost-effectiveness 
ratios (ICER) were calculated. Therapy cost was calculated by considering medication 
cost (by taking an average reimbursement amount provided by Medicare part D and 
private insurances), physician visit cost, cost associated with adverse drug events, and 
cost due to lack of patient persistency (based on expected annual drug usage). Effec-
tiveness measure considered was percent reduction in intraocular pressure (IOP) from 
baseline. A one-way sensitivity analysis was performed by varying cost by 25% to 
take into consideration the potential wastage, overutilization, underutilization, and 
various differences in IOP reduction in patients. RESULTS: Mean average percent IOP 
reduction for LT, DT and BT was 6.3%, 4.3% and 4.6%, respectively. The total cost 
of therapy for LT, DT and BT was estimated to be $711, $935, and $1099, respec-
tively. ICER analyses indicated a gain of $111.5 for change from DT to LT, while a 
change from BT to LT indicated a gain of $228. The results remained robust after 
sensitivity analysis. CONCLUSIONS: In our study, LT was found to be more cost-
effective compared to DT and BT. Managed care payers may wish to prioritize ﬁxed-
combination therapies used for glaucoma considering medication related adverse 
events and persistency. Further, research taking into account various other costs 
should be conducted to provide better evidence.
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COST EFFICACY OF USTEKINUMAB IN TREATMENT OF MODERATE 
TO SEVERE PLAQUE PSORIASIS IN TURKEY
Tatar M1, Sarioz F2
1Hacettepe University, Ankara, Turkey, 2Janssen-Cilag, Istanbul , Turkey
OBJECTIVES: Psoriasis is a chronic and incurable systemic inﬂammatory disease with 
devastating impact on overall health of patients. Ustekinumab, a fully human mono-
clonal antibody, is the ﬁrst treatment to speciﬁcally target IL-12 and IL-23.The efﬁcacy 
and safety of ustekinumab have been studied in three Phase III, international, ran-
domised, controlled clinical trials and its clinical superiority over etanercept was 
demonstrated in a Phase III trial (ACCEPT). The objective of this study was to 
compare cost efﬁcacy of subcutaneously administered biologics by using a cost per 
responder model in Turkey. The study was undertaken from a Turkish health care 
payer perspective. METHODS: In the cost per responder model, clinical efﬁcacy was 
measured by improvement in the Psoriasis Area and Severity Index (PASI 75 response) 
from randomized, controlled trials. An indirect comparison using a Mixed Treatment 
Comparison (MTC) meta-analysis was used to estimate response rates. Comparators 
used in the model were ustekinumab, etanercept, adalimumab, and efalizumab. 
Ustekinumab efﬁcacy has been analyzed based on patient’s weight for patients with a 
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body weight less or equal to 100 kg who received 45 mg. Additionally, PASI responses 
from ACCEPT between ustekinumab and etanercept were used. Costs in the model 
included drug acquisition costs only. RESULTS: In the weight-based efﬁcacy analysis, 
ustekinumab 45 mg treatment had the highest PASI 75 response. Under a ﬁxed budget 
of TL 1,000,000, it is possible to treat more patients successfully (achieving a PASI75) 
with ustekinumab 45 mg than with etanercept 50 mg biweekly. In both the ﬁrst year 
of therapy and in the maintenance year, ustekinumab 45 mg is more cost-effective 
compared to etanercept 50 mg biweekly. CONCLUSIONS: According to the results 
of the cost per responder model, ustekinumab 45 mg is more cost-effective than 
etanercept 50 mg biweekly and therefore a preferable alternative in the treatment of 
moderate to severe plaque psoriasis in Turkey.
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EFFICIENCY (COST/EFFICACY) OF BIOLOGIC AGENTS IN THE 
TREATMENT OF MODERATE TO SEVERE PSORIASIS
Lázaro P1, Blasco AJ1, Ferrándiz C2, García A3, Liso J4
1Advanced Techniques in Health Services Research (TAISS), Madrid, Spain, 2Universidad 
Autónoma de Barcelona, Badalona, Barcelona, Spain, 3Universidad Autónoma de Madrid, 
Madrid, Spain, 4Complejo Hospitalario de Badajoz, Badajoz, Spain
OBJECTIVES: To estimate the cost/efﬁcacy ratios of biologics authorized in Spain in 
2009 (adalimumab, etanercept, inﬂiximab and ustekinumab) in the management of 
moderate-severe psoriasis. METHODS: A model for economic evaluation (decision 
tree) was built for the treatments according to the available scientiﬁc evidence. The 
payer perspective (National Health System) was used, only considering drug cost and 
assuming zero cost for placebo. In the case of weight-dependent dosing, the weight of 
the study participants was adjusted by age and sex to the standard Spanish population 
corrected by the weight increment in individuals with psoriasis. The Psoriasis Area 
Severity Index (PASI) 75 criterion (improvement of 75% from baseline PASI) was used 
as indicator of efﬁcacy. The incremental efﬁcacy (calculated as the proportion of 
patients responding with PASI 75 criterion in the biologic group minus the proportion 
who respond in the placebo group) was assigned according to the outcomes of clinical 
trials at the period of time deﬁned in the primary efﬁcacy outcome. When more than 
one trial was available per treatment, a meta-analysis was undertaken (DerSimonian-
Laird method). Uncertainty was tested by deterministic sensitivity analysis, building 
scenarios with the conﬁdence intervals at 95% for costs and efﬁcacy. RESULTS: The 
incremental efﬁcacy in the baseline scenario ranged from 31.19 % (etanercept: 25 mg 
twice a week at 12 weeks of treatment) to 78.35% (inﬂiximab: 5 mg/Kg at 24 weeks 
of treatment). The efﬁciency in terms of cost/efﬁcay, in the baseline scenario, ranged 
from 38,013 (adalimumab at 16 weeks) and 317,981 (ustekinumab: 90 mg at 12 
weeks) per PASI 75 responder. In the sensitivity analysis, adalimumab remains as the 
most efﬁcient biologic on the most and least favourable scenarios. CONCLUSIONS: 
Of the biologic agents authorized in Spain for treating moderate-severe psoriasis, the 
most efﬁcient in terms of cost/efﬁcacy is adalimumab.
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PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS: 
ANALYSIS FROM THE ACCEPT TRIAL
Feldman SR1, Augustin M2, Martin S3, Szapary P4, Schenkel B5
1Wake Forest University, Winston-Salem, NC, USA, 2University Clinics of Hamburg, 
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OBJECTIVES: To compare the cost per responder of ustekinumab (UST) versus 
etanercept (ETN) based on head-to-head data from the ACCEPT trial, which demon-
strated greater efﬁcacy of two doses of UST, 45 mg and 90 mg at weeks 0 and 4, 
versus ETN, 50 mg twice weekly through week 12, in patients with moderate-to-
severe plaque psoriasis (PsO). METHODS: Efﬁcacy results (proportion of patients 
achieving at least 75% improvement in the Psoriasis Area and Severity Index [PASI75]) 
were obtained from the ACCEPT trial (n = 903). Given the unique dosing of UST 
(weeks 0, 4, 16, and q12 weeks thereafter), we determined the cost per PASI75 
response at week 16, the appropriate decision point for determining whether to 
proceed with a third dose. Week 16 PASI75 results were assumed to be equal to week 
12 efﬁcacy from ACCEPT; previously published randomized controlled trials have 
reported similar observations for both drugs. Dosing through week 12 was per 
ACCEPT. Dosing for weeks 13–16 was assumed to be per labeled indication in PsO. 
US wholesale acquisition cost (WAC) was used for calculating costs. The analyses used 
weight-based efﬁcacy results for UST (45 mg ≤100 kg and 90 mg >100 kg) and overall 
efﬁcacy for ETN to align with the respective approved labels for each drug. RESULTS: 
In ACCEPT, 209 patients received UST 45 mg, 347 received UST 90 mg, and 347 
received ETN. Baseline demographics and disease characteristics were comparable 
between groups. Twenty-eight percent of patients were >100 kg. The PASI75 
responses at week 12 were 72% for UST 45 mg in patients ≤100 kg and 65% for 
UST 90 mg in patients >100 kg, compared with 57% for the ETN group. At week 
16, the WAC per PASI75 response was $17,009 for UST-treated patients and $19,140 
for ETN-treated patients. CONCLUSIONS: WAC per PASI75 response was lower for 
UST relative to ETN through 16 weeks in PsO patients.
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COST-UTILITY ANALYSIS OF MAINTENANCE TREATMENT WITH 
TACROLIMUS OINTMENT IN ADULTS AND CHILDREN WITH 
MODERATE AND SEVERE ATOPIC DERMATITIS
Chambers C1, Bentley A2
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OBJECTIVES: A twice weekly maintenance treatment strategy with tacrolimus oint-
ment for atopic dermatitis signiﬁcantly delayed and reduced the number of disease 
ﬂares over a 12-month period compared with the standard reactive tacrolimus treat-
ment strategy. The aim of this post hoc analysis was to evaluate the cost-effectiveness 
of the maintenance strategy versus the reactive strategy in adults and children with 
moderate and severe atopic dermatitis (AD). METHODS: The evaluation was per-
formed using a decision analytic model based on the results of two pivotal phase III 
trials that were conducted in adults and children receiving 0.1% and 0.03% tacrolimus 
ointment, respectively. Clinical data were taken from the clinical trials and utility data 
were derived from a published source. The time horizon was 12 months; costs and 
utilities were applied to the treatment period and to any remaining days in the 
12-month period post-tacrolimus discontinuation. Sensitivity analyses assessed the 
degree of uncertainty around the results. The analysis was conducted from the perspec-
tive of the UK National Health Service. RESULTS: In the base-case analysis for both 
adults and children with moderate and severe AD, the maintenance treatment strategy 
with tacrolimus ointment was dominant over the reactive treatment strategy in that 
it was more effective and less costly. In univariate sensitivity analyses, for all patient 
groups, few parameters when varied between the value of their upper and lower 
conﬁdence interval resulted in incremental cost-effectiveness ratios (ICERs) above 
zero. Probabilistic sensitivity analyses demonstrated that the probability of tacrolimus 
maintenance treatment being dominant over the reactive treatment strategy was; 76% 
for adults with moderate AD, 89% for adults with severe AD, 75% for children with 
moderate AD and 54% for children with severe AD. CONCLUSIONS: Maintenance 
use of tacrolimus ointment is a dominant treatment strategy compared with reactive 
use, providing incremental health beneﬁts at a lower cost.
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MODELING THE COST-EFFECTIVENESS OF USTEKINUMAB FOR 
MODERATE TO SEVERE PLAQUE PSORIASIS IN US
Verma S, Dharmarajan S, Yang Y
University of Mississippi, University, MS, USA
OBJECTIVES: To determine cost-effectiveness of Ustekinumab in patients with mod-
erate-to-severe plaque psoriasis in comparison with Etanercept from third-party payer 
perspective. METHODS: A cost-utility analysis was performed using a Markov model 
which compared cost per QALY of Ustekinumab (45 mg at week 0 and 4, then every 
12 weeks thereafter) and Etanercept (50 mg twice weekly for the ﬁrst 12 weeks and 
then once a week). The probabilities of treatment response were taken from the 
ACCEPT trial (which compared both the drugs); while utility values for different 
stages were obtained from published studies. A 12 week paradigm for the base case 
of each agent was developed on the basis of dosage administration, laboratory moni-
toring utilized in the Randomized Clinical Trials and manufacturer’s published guide-
lines. The cost of therapies included 2009 AWP (average wholesale price) of both the 
drugs, and cost of physician visits and lab were inﬂated to 2009 from 2006 Medicare 
clinical laboratory fee schedule and physician reimbursement schedule (which used 
mean US reimbursement). Since the time frame of the analysis was only 12 weeks, the 
costs of long-term side effects and adverse events were not included. Extrapolations 
were made to evaluate the cost-effectiveness of two drugs over a period of ﬁve years, 
with costs and beneﬁts discounted at 3.5% per annum. Various sensitivity analysis 
were carried out to test the robustness of the model. RESULTS: The QALYs gained 
by Ustekinumab in comparison to Etanercept over a period of 5 years were 0.23, at 
an incremental cost-effectiveness ratio (ICER) of $65,693.59 per QALY gained.
Further sensitivity analysis conﬁrmed the robustness of results. CONCLUSIONS: 
Although as per the present analysis, Ustekinumab might not appear to be more cost 
effective than Etanercept, but it may be recommended due to modest increase in 
QALYs and convenient dosage pattern of once in 12 weeks.
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VALIDITY AND RELIABILITY OF THE VISUAL FUNCTION 
QUESTIONNAIRE UTILITY INDEX IN INDIVIDUALS WITH  
AGE-RELATED MACULAR DEGENERATION
Gries K1, Patrick D1, Kowalski J2, Sullivan S1
1University of Washington, Seattle, WA, USA, 2Allergan, Irvine, CA, USA
OBJECTIVES: The Visual Function Questionnaire Utility Index (VFQ-UI) is a vision-
speciﬁc preference measure developed from the National Eye Institute Visual Function 
Questionnaire 25 (NEI VFQ-25). The objective of this analysis was to assess the 
validity and reliability of the VFQ-UI in individuals with age-related macular degen-
eration (AMD). METHODS: Post-hoc analysis using data collected from a multi-
center, randomized controlled trial of 138 individuals with AMD. The NEI VFQ-25, 
HUI, and EQ-5D were administered at baseline and day 1 visits. The NEI VFQ-25 
dataset was used to calculate utility values using the VFQ-UI algorithm. Validity was 
assessed using convergent validity with HUI2, HUI3 and visual acuity and discrimi-
nant validity with the EQ-5D and known groups of visual acuity. Reliability was 
